Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Futuximab, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tosatoxumab, an antibody targeting Staphylococcus aureus Toxin A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Modotuximab, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Dapirolizumab, an antibody targeting CD40L.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Emactuzumab, an antibody targeting CSF1R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pamrevlumab, an antibody targeting CTGF.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Monalizumab, an antibody targeting NKG2A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Oleclumab, an antibody targeting CD73.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ianalumab, an antibody targeting BAFF-R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cetrelimab, an antibody targeting PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bemarituzumab, an antibody targeting FGFR2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nadunolimab, an antibody targeting IL1RAP.